Company profile: Inscopix
1.1 - Company Overview
Company description
- Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
Products and services
- NVue System: Dual-color imaging for simultaneous study of two distinct brain signals in freely behaving animals, featuring expanded data storage capacity enabling extended longitudinal experiments
- Multicolor Data Processing: Software-based analysis for miniscope data using PCA/ICA or CNMFe for cell identification, plus filtering tools and longitudinal registration to track cells across sessions
- LScape Module: Add-on expanding nVue System’s field of view and working distance for cortical brain region imaging, optimizing coverage of larger areas during experiments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inscopix
iPierian
HQ: United States
Website
- Description: Provider of a drug discovery platform leveraging induced pluripotent stem cells to discover and develop therapies for neurodegenerative diseases, including SMA, ALS, and Parkinson's, addressing other major unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iPierian company profile →
Jupiter Neurosciences
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting Alzheimer's and rare neurological disorders, including JOTROL, an oral micellar resveratrol formulation designed to deliver therapeutic doses without side effects. The company pursues a pipeline strategy using a Phase I study to enable trials for three rare diseases and mild cognitive impairment to proceed directly to Phase II.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jupiter Neurosciences company profile →
NeuroOne Medical Technologies
HQ: United States
Website
- Description: Provider of neurosurgical technologies, including the OneRF Radiofrequency Ablation System for bedside monitoring, mapping, and ablation to create radiofrequency lesions in nervous tissue for epilepsy treatment; the Evo sEEG Electrode for recording brain activity and identifying seizure foci for epilepsy treatment; and the Evo Cortical Electrode for ECoG/iEEG surgeries to monitor, record, and stimulate the brain surface for less than 30 days.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroOne Medical Technologies company profile →
BioQ Pharma
HQ: United States
Website
- Description: Provider of pre-filled, ready-to-use infusion delivery systems and medicines. Offerings include invenious, a platform for infusible medicines to simplify infusion and enhance safety and sterility; Ropivacaine Readyfusor, a pre-filled infusion for surgical procedures as a safer, more efficient alternative to fillable pain pumps; and invenious/propofol, a ready-to-use infusion with programmable flow and bolus for procedural anesthesia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioQ Pharma company profile →
Synchroneuron
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies under development for tardive dyskinesia and other related movement disorders, including lead candidate SNC-102, a sustained-release formulation of acamprosate calcium in phase 2 trials for tardive dyskinesia and Tourette syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synchroneuron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inscopix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inscopix
2.2 - Growth funds investing in similar companies to Inscopix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inscopix
4.2 - Public trading comparable groups for Inscopix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →